The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review

Boris Dinkov, Diana Pendicheva-Duhlenska

Open source

DOI
10.3390/biomedicines14040806
Published
2026-04-01
Container
Biomedicines
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/biomedicines14040806,
  title = {The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review},
  author = {Boris Dinkov and Diana Pendicheva-Duhlenska},
  year = {2026},
  journal = {Biomedicines},
  doi = {10.3390/biomedicines14040806},
  url = {https://doi.org/10.3390/biomedicines14040806}
}

RIS

TY  - JOUR
TI  - The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review
AU  - Boris Dinkov
AU  - Diana Pendicheva-Duhlenska
PY  - 2026
JO  - Biomedicines
DO  - 10.3390/biomedicines14040806
UR  - https://doi.org/10.3390/biomedicines14040806
ER  - 

APA

Dinkov, B., & Pendicheva-Duhlenska, D. (2026). The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review. Biomedicines. https://doi.org/10.3390/biomedicines14040806

Source records